IWP L6 (GMP)

IWP L6 (GMP) (Porcn Inhibitor III (GMP)) is IWP L6 (HY-15825) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IWP L6 (Porcn Inhibitor III) is a Porcupine (Porcn) inhibitor with an EC₅₀ of 0.5 nM. IWP L6 disrupts well-established Wnt-dependent developmental processes of embryonic and juvenile zebrafish^[1]. In Vitro:IWP L6 (Porcn Inhibitor III) (GMP) effectively suppressed the phosphorylation of dishevelled 2 (Dvl2) in HEK293 cells, a biochemical event associated with many Wnt-dependent cellular responses. IWP L6 (GMP) inhibits Wnt mediated branching morphogenesis in cultured embryonic kidneys ^[1]. In Vivo:IWP L6 (Porcn Inhibitor III) (GMP) is stable in human plasma over 24 h, it is rapidly metabolized in rat plasma (t_1/2 = 190 min), murine plasma (t_1/2 = 2 min), and the murine liver S9 fractions (t_1/2 = 26 min). The major metabolites are the amide cleavage products. Similar species-dependent metabolitic profiles due to the involvement of carboxylesterase (CES) have been reported with other drug candidates. Despite its modest metabolic stability in mouse-derived plasma, IWP L6 (GMP) is highly active in zebrafish. IWP L6 exhibits more potent activity^[1].